Search for Actavis and
    1. November 21, 2014

      Allergan deal sits well on Actavis chief’s ‘Monopoly board’

      When Paul Bisaro, executive chairman of Actavis, raised the idea of buying Allergan this summer, he prompted some surprise...

    2. November 18, 2014

      Actavis’ dealmaking builds drug powerhouse

      Just two years ago Actavis, then known as Watson Pharmaceuticals, was a run-of-the-mill maker of generic drugs with a market...

    1. November 17, 2014

      Allergan sees off Valeant by sealing $66bn deal with Actavis

      Actavis-Allergan deal Allergan ended the year’s ugliest and longest-running takeover battle on Monday after the Botox maker...

    2. November 17, 2014

      Allergan-Actavis deal follows battle for soul of pharma

      Actavis-Allergan deal The sale of Allergan to Actavis for about $66bn is set to be the biggest takeover in a frantic year of...

    3. November 16, 2014

      Actavis to pay $66bn for Allergan

      Allergan, the maker of Botox, has agreed to sell itself in a $66bn deal with fellow drugs group Actavis , with rival Valeant...

    4. November 7, 2014

      Pharma wars: upset stomach

      It’s not a good sign when a bowel medicine company feels bloated. Salix Pharmaceuticals, a drug company focused on...

    5. November 6, 2014

      Perrigo joins wave of OTC drug deals

      Perrigo said it had joined the big league of global over-the-counter drugmakers after agreeing a €3.6bn acquisition of Omega...

    6. October 16, 2014

      Tax changes roil inversion deals

      The sudden collapse of AbbVie’s proposed $54bn takeover of rival drugmaker Shire does not necessarily signal that the Obama...

    7. October 9, 2014

      Takeover target Allergan raises guidance

      Allergan, the maker of blockbuster wrinkle treatment Botox, has boosted its earnings forecast for the third quarter and...

    8. October 8, 2014

      Valeant and Pershing look to sweeten Allergan bid by $4.5bn

      Valeant Pharmaceuticals and Bill Ackman’s Pershing Square are considering sweetening their offer for Allergan by $4.5bn, as...

    9. October 3, 2014

      Salix pulls deal amid US tax crackdown

      A $2.7bn deal between drugmakers Salix of the US and Cosmo of Italy has become the first victim of President Barack Obama’s...

    10. September 28, 2014

      Drugs groups trapped in tangled M&A web

      When Valeant offered almost $46bn to buy Allergan in April, it seemed like a large but relatively straightforward deal....

    11. July 14, 2014

      Mylan in $5.3bn Abbott Laboratories deal

      US pharmaceuticals group Mylan has agreed to pay $5.3bn for the generic drugs business of Abbott Laboratories, in another...

    12. February 26, 2014

      Hedge funds should not be the only activist investors

      At 78, Carl Icahn shows little sign of retiring, or of becoming more polite. After finally prodding Forest Labs into a $25bn...

    13. February 21, 2014

      Carl Icahn, obsessive activist investor

      Steven Goldstone, when he was chief executive of RJR Nabisco, used to call the appearance of Carl Icahn “a rite of spring”....

    14. February 21, 2014

      Letter from Lex: the end of investing

      If a company that has designed a single successful mobile phone game can be worth $5bn, anything can be worth anything, and...

    15. February 19, 2014

      Eli Lilly jumps after cancer drug trial

      Shares in Eli Lilly climbed after the US pharmaceuticals group said a study of a lung cancer treatment increased survival...

    16. FT Alphaville

      February 18, 2014

      The Closer

      FURTHER FURTHER READING - Kevin Roose crashes a Wall Street secret society. - Minimum wage by the numbers. - Arnold Kling...

    17. February 18, 2014

      Actavis chief Bisaro finds prescription for growth

      Paul Bisaro, the outspoken chief executive of drugs company Actavis, has quickly gained a reputation as an ambitious...

    18. February 18, 2014

      Actavis / Forest: roll up, tax down

      Buy drug company, cut operating costs, cut research spending, pay less tax, watch stock go up. It is a simple plan, and...

    19. February 18, 2014

      Actavis buys Forest Laboratories for $25bn

      Actavis, the highly acquisitive Dublin-based drugs maker, has agreed to buy New York’s Forest Laboratories for $25bn, its...

    20. August 25, 2013

      Amgen’s $10.5bn takeover of Onyx approved by both boards

      Amgen said on Sunday night that its takeover of Onyx, the US cancer drug developer, at $125 a share had been approved by...

    21. July 29, 2013

      Perrigo / Elan: tax shopping

      Remember the quaint old days, when mergers aimed for cost savings? Ah, the deals of yesteryear. It is all about taxes now....

    22. June 19, 2013

      Lundbeck fined €94m for ‘pay for delay’ deals to rivals

      European regulators have fined Lundbeck, the Danish pharmaceutical company, €94m for paying rivals to delay cut-price...

    23. June 17, 2013

      Payments to delay generic drug rivals to be scrutinised

      Payments by drug companies to delay generic competition will be open to fresh antitrust scrutiny in the US, following a...

    24. May 28, 2013

      Generic drugs: Watchdogs probe pay-for-delay deals

      Sir Andrew Witty winces at the term, but the chief executive of GlaxoSmithKline is one of a growing number of chief...

    25. May 24, 2013

      Valeant nears $9bn Bausch & Lomb deal

      Valeant is closing in on a deal to acquire Bausch & Lomb for about $9bn, said people familiar with the matter. The deal came...

    26. May 20, 2013

      Actavis / Warner Chilcott: simple medicine

      Hopefully it is as sensible as it looks. Warner Chilcott has agreed to be bought by Actavis for $8.5bn. The deal lacks flash...

    27. May 20, 2013

      Dealmaking fails to send Wall St higher

      US stocks saw muted losses that sent the S&P retreating from record levels, despite a burst of dealmaking to start the week....

    28. May 20, 2013

      Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal

      Actavis sought to fend off takeover threats by purchasing Dublin-based rival Warner Chilcott in a $5bn deal designed to turn...

    29. May 10, 2013

      Actavis in talks to buy Warner Chilcott

      Actavis, the generic drugmaker, is in early discussions to buy Warner Chilcott, a pharmaceuticals company valued at more...

    30. April 27, 2013

      Valeant and Actavis held $35bn merger talks

      Valeant Pharmaceuticals International and generic drugmaker Actavis were recently working on a merger that would have...

    31. April 2, 2013

      AstraZeneca loses US drug patent judgment

      AstraZeneca’s portfolio of patent-protected drugs has been trimmed back after the pharmaceuticals group lost a legal...

    32. June 25, 2012

      Shire shares slump as rival drug approved

      More than £1bn was wiped from Shire’s market capitalisation on Monday after the US Food and Drug Administration widened the...

    33. June 25, 2012

      Ephemeral fortresses

      Angus Russell, chief executive of Shire, is a sand castle builder, like all drug company bosses. The rising tide of generic...

    34. June 18, 2012

      Drug groups warn over new EU law

      European patients face the prospect of medicine shortages if legislation designed to ensure the high quality of ingredients...

    35. May 6, 2012

      Generic rivals are also being blown off-course

      The strong headwinds facing big pharmaceutical groups are due in part to pressure from the rise of generic rivals. But many...

    36. May 6, 2012

      HgCapital puts up Mercury Pharma for sale

      Mercury Pharma, the generic drugs group previously known as Goldshield, has been put up for sale by its private equity owner...

    37. May 3, 2012

      Sandoz gains dermatology lead with Fougera

      Novartis’s generic drugs division Sandoz has agreed to buy Fougera Pharmaceuticals for $1.53bn in cash in a deal that...

    38. April 26, 2012

      Watson expects earnings boost from deal

      Watson expects to boost earnings following completion of its €4.5bn agreed takeover of Actavis, which has created one of the...

    Search for Actavis and